| Drug General Information |
| Drug ID |
D0V0JR
|
| Former ID |
DIB016417
|
| Drug Name |
Cadi-05
|
| Synonyms |
Mycobacterium w; Poly-TLR agonist polyantigenic vaccine (cancer), Cadila; Poly-toll-like receptor agonist polyantigenic vaccine (cancer), Cadila
|
| Drug Type |
Vaccine
|
| Indication |
Prostate cancer [ICD9: 185; ICD10:C61]
|
Phase 3 |
[1]
|
|---|
| Company |
Cadila Pharmaceuticals Ltd
|
| Target and Pathway |
| Target(s) |
Toll-like receptor 9 |
Target Info |
|
[2]
|
|---|
| Toll-like receptor 2 |
Target Info |
|
[2]
|
| Toll-like receptor 4 |
Target Info |
|
[2]
|
|
KEGG Pathway
|
Toll-like receptor signaling pathway
|
|
Chagas disease (American trypanosomiasis)
|
|
African trypanosomiasis
|
|
Malaria
|
|
Tuberculosis
|
|
Measles
|
|
Herpes simplex infectionhsa04145:Phagosome
|
|
PI3K-Akt signaling pathway
|
|
Legionellosis
|
|
Leishmaniasis
|
|
Toxoplasmosis
|
|
Amoebiasis
|
|
Hepatitis B
|
|
Herpes simplex infection
|
|
Proteoglycans in cancer
|
|
Inflammatory bowel disease (IBD)
|
|
Rheumatoid arthritishsa04064:NF-kappa B signaling pathway
|
|
HIF-1 signaling pathway
|
|
Phagosome
|
|
Pathogenic Escherichia coli infection
|
|
Salmonella infection
|
|
Pertussis
|
|
Influenza A
|
|
Rheumatoid arthritis
|
|
NetPath Pathway
|
BCR Signaling PathwayNetPath_16:IL4 Signaling Pathway
|
|
TCR Signaling PathwayNetPath_17:IL5 Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
IL4 Signaling Pathway
|
|
PANTHER Pathway
|
Toll receptor signaling pathwayP00054:Toll receptor signaling pathwayP00054:Toll receptor signaling pathway
|
|
Pathway Interaction Database
|
Endogenous TLR signalingtoll_endogenous_pathway:Endogenous TLR signaling
|
|
Reactome
|
PI3K Cascade
|
|
Trafficking and processing of endosomal TLR
|
|
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling
|
|
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
|
|
MyD88 dependent cascade initiated on endosomeR-HSA-1461957:Beta defensins
|
|
MyD88:Mal cascade initiated on plasma membrane
|
|
Toll Like Receptor TLR6:TLR2 Cascade
|
|
MyD88 deficiency (TLR2/4)
|
|
IRAK4 deficiency (TLR2/4)R-HSA-140534:Ligand-dependent caspase activation
|
|
Toll Like Receptor 4 (TLR4) Cascade
|
|
MyD88-independent TLR3/TLR4 cascade
|
|
TRIF-mediated programmed cell death
|
|
IRAK4 deficiency (TLR2/4)
|
|
Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
|
|
IKK complex recruitment mediated by RIP1
|
|
TRAF6 mediated induction of TAK1 complex
|
|
WikiPathways
|
Toll-like receptor signaling pathway
|
|
Toll-Like Receptors Cascades
|
|
MyD88 dependent cascade initiated on endosome
|
|
Trafficking and processing of endosomal TLR
|
|
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
|
|
Regulation of toll-like receptor signaling pathwayWP75:Toll-like receptor signaling pathway
|
|
IL1 and megakaryotyces in obesity
|
|
Human Complement System
|
|
MyD88:Mal cascade initiated on plasma membrane
|
|
Defensins
|
|
MyD88-independent cascade
|
|
Primary Focal Segmental Glomerulosclerosis FSGS
|
|
Spinal Cord Injury
|
|
Corticotropin-releasing hormone
|
|
Pathogenic Escherichia coli infection
|
|
Regulation of toll-like receptor signaling pathway
|
| References |
| REF 1 | ClinicalTrials.gov (NCT00810849) A Trial of Adjunctive Prednisolone and Mycobacterium w Immunotherapy in Tuberculous Pericarditis. U.S. National Institutes of Health. |
|---|
| REF 2 | Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716. |
|---|
